Imaging Dopamine Release in Depression

PHASE4CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

July 31, 2017

Conditions
Major Depressive Disorder
Interventions
DRUG

Pramipexole

Dose will be started at 0.125 mg bid, and increased by 0.25 mg/day every 3-4 days to a target range of 1.0 - 2.5 mg/day.

Trial Locations (1)

10032

New York State Psychiatric Institute, New York

All Listed Sponsors
collaborator

Columbia University

OTHER

collaborator

Research Foundation for Mental Hygiene, Inc.

OTHER

collaborator

Mclean Hospital

OTHER

collaborator

Icahn School of Medicine at Mount Sinai

OTHER

collaborator

National Institute of Mental Health (NIMH)

NIH

lead

New York State Psychiatric Institute

OTHER

NCT02033369 - Imaging Dopamine Release in Depression | Biotech Hunter | Biotech Hunter